A carregar...
Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
Sorafenib and lenvatinib are approved for first‐line treatment of patients with advanced hepatocellular carcinoma (HCC), and the efficacy of atezolizumab plus bevacizumab has been demonstrated versus sorafenib. Over time, first‐line treatment frequently fails, and regorafenib, cabozantinib, ramuciru...
Na minha lista:
| Publicado no: | Liver Int |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7496898/ https://ncbi.nlm.nih.gov/pubmed/32432830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14533 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|